PMID- 9206096 OWN - NLM STAT- MEDLINE DCOM- 19970730 LR - 20041117 IS - 0366-6999 (Print) IS - 0366-6999 (Linking) VI - 109 IP - 7 DP - 1996 Jul TI - The role of human leukocyte antigen in susceptibility and clinical manifestations of sarcoidosis. PG - 515-8 AB - OBJECTIVE: To investigate the correlation of human leukocyte antigen (HLA) with susceptibility and clinical manifestations of sarcoidosis. MATERIAL AND METHODS: Fifty-five patients with sarcoidosis and one hundred and six normal subjects were investigated. Genomic DNAs were purified using the proteinase K-phenol extraction method. DNA samples were amplified by the polymerase chain reaction (PCR) procedure using the DRB1 group specific primer pairs. RESULTS: The gene frequency of HLA-DR5 increased significantly in patients with sarcoidosis (P < 0.01), and HLA-DR7 decreased (P < 0.05). Gene frequencies of HLA-DR9 and HLA-DR5 increased remarkably in male patients and in patients with stage I and stage IIa, respectively (both P < 0.05). CONCLUSIONS: It is suggested that HLA-DR gene might contribute to the susceptibility as well as various clinical manifestations of sarcoidosis. FAU - Xu, Z AU - Xu Z AD - Department of Respiratory Medicine, Peking Union Medical College (PUMC) Hospital, Beijing. FAU - Zhao, Y AU - Zhao Y FAU - Zhu, X AU - Zhu X FAU - Qiu, C AU - Qiu C FAU - Luo, W AU - Luo W FAU - Zhu, Y AU - Zhu Y LA - eng PT - Journal Article PL - China TA - Chin Med J (Engl) JT - Chinese medical journal JID - 7513795 RN - 0 (HLA-DR5 Antigen) RN - 0 (HLA-DR7 Antigen) SB - IM MH - Adult MH - Aged MH - CD4-Positive T-Lymphocytes/immunology MH - Disease Susceptibility MH - Female MH - Gene Frequency MH - HLA-DR5 Antigen/genetics/*physiology MH - HLA-DR7 Antigen/genetics/*physiology MH - Humans MH - Male MH - Middle Aged MH - Sarcoidosis, Pulmonary/*genetics EDAT- 1996/07/01 00:00 MHDA- 1996/07/01 00:01 CRDT- 1996/07/01 00:00 PHST- 1996/07/01 00:00 [pubmed] PHST- 1996/07/01 00:01 [medline] PHST- 1996/07/01 00:00 [entrez] PST - ppublish SO - Chin Med J (Engl). 1996 Jul;109(7):515-8.